-
Rail journey offers a slower route to a Berlin city break
-
Energy bill plan could use HMRC income data to target support
-
Arsenal control title race as Manchester United fall into bottom three
-
Business owner earning £6,000 a month tackles £70,000 debt
-
Suspected Krakow gunman dies after attack that killed six
-
Nvidia chief faces inquiry after disclosing affair with suspected Chinese agent
-
Carrick backs Dalot after hostile reception from Manchester United fans
-
Comet returns as online electrical marketplace 14 years after collapse
-
Aston Villa Defy History With Rare Victory at Old Trafford
-
Brussels Education Unions Schedule Major November Protest Over Funding and Reforms
-
Crowds Gather at San Francisco Park for Elizabeth Holmes Lookalike Tournament
-
Hancock Health Expands Robot Specimen Delivery to Parkway Building, Adding Scheduled and On-Demand Runs to the Lab
-
Releaf Unveils UK-first THCV for Weight Management
-
Gabriel Provides Corporate Update
-
AsiaFIN's Insite MY Holdings and MENA Insite MY Sign Distributorship Agreement and Announce Second Bank Customer in Saudi Arabia
-
Ai4 Celebrates Successful Debut of Applied AI Research Conference (AAIRC), Bridging Academic Research and Industry Innovation
-
Medicus Pharma to Highlight Rationale for CD228V Co-Development and License Agreement
-
Nextech3D.ai Closes $720,000 Management-Led Private Placement
-
CoTec Holdings Corp. Notes HyProMag USA Advances North Texas Rare Earth Magnet Facility With First Major Equipment Delivery
-
Silver Storm Reports Concentrate Deliveries from La Parrilla
-
Ispire Technology Inc. Reports First Quarter Fiscal Year 2027 Financial Results
-
HyProMag USA Advances North Texas Rare Earth Magnet Facility With First Major Equipment Delivery
-
Hillcrest and Equipmake Sign Definitive Agreement to Jointly Develop and License ZVS Inverter Technology for Heavy-Duty Electric Vehicles
-
Tintina Mines Intersects 460m at 0.50% CuEq at the Dos Amigos Copper-Gold Project in Chile
-
Pace Launches Three-Business-Day Culture-Based 'L. pneumophila' Testing
-
Opti Digital Launches NEXA, an AI-Powered Intelligence Layer
-
DataMEDS AI Announces Corexa Pharmacy's First Commercial Sale of Compounded Peptides Under FDA Enforcement Discretion Policy
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 09
-
Making Your Home Safer for Aging Parents: Accessibility Renovations That Add Value
-
New 401k Gold IRA Investment Guide Explains the Best Way to Invest in Gold for Retirement (2026 Update)
-
United States Antimony Corporation Announces Webcast Time set for Thursday, November 12, 2026 at 4:15 PM ET to Report on Third Quarter and Nine Months Ended September 30, 2026 Financial and Operating Results
-
Pacific Edge Labs Publishes More Than 120 Independent Lab Reports, Each Listed With the Testing Lab's Own ID
-
Regentis Signs Exclusive Distribution Agreement with AMI Technologies to Commercialize GelrinC(R) in Israel
-
Modular Medical Completes Comprehensive Patient Market Research Study with Thrivable, Reinforcing Strong Interest in Simplified Insulin Delivery
-
Shelfietech Launched New Retail Software Platform
-
A Holiday-Season Moment for Penny-Stock Followers and Microcap Visionaries as Elektros Moves Its EV Patent Forward
-
Dolphin Subsidiary 42West Drives Global Communications Behind Box Office Leaders Godzilla Minus Zero and Ramayana
-
Visterra Landscape Group Expands Into Arkansas With Strategic Investment In Little Rock Landscape
-
Santa Claus Has Come Early: Elektros Brings An Early-Christmas Spark To Its Patented EV Charging Vision
-
SMX Is Building a Verifiable Identity Layer for Fashion, From Cotton Fields to Luxury Resale
-
Gladstone Land Corporation Earnings Call and Webcast Information
-
The Metals Royalty Company to Host Corporate Update Webinar on November 16, 2026
-
Aptevo Presents Preclinical Data at SITC 2026 Showing Potential to Overcome Immune Suppression in Solid Tumors
-
Eylsia Nicolas Launches Global "Wake Me Up" Franchise After Surpassing 100 Million Meta Views in One Week
-
BioLargo Targets Growing Industrial PFAS Market with MasterClass at International Water Conference
-
Jericho Energy Ventures to Participate in Cantor Convergence 4th Annual Crypto and AI Infrastructure Conference
-
IGC Pharma Reports Third Quarter 2026 Financial Results and Provides Business Update
-
Tectonic Metals Adds Mine Development and Alaska Native Partnership Leaders Ahead of 2027 Mineral Resource Estimate and Preliminary Economic Assessment
-
iPS Cell Research Accelerates Drug Discovery for ALS and Spinal Cord Injury
-
Central Tokyo Apartment Rents Forecast to Rise 11% by 2030
Strive Pharmacy Expands Footprint with Acquisition of Alachua Facility and New Tampa Location, Cementing Leadership in Patient-Focused Compounding Innovation
With more than 700,000 square feet of advanced operations within the next 12 months, Strive solidifies its position as a national leader in pharmaceutical compounding while pursuing its mission to elevate patient care through innovation, scale, and quality.
GILBERT, AZ / ACCESS Newswire / November 4, 2025 / Strive Pharmacy, a leader in personalized healthcare solutions, today announced a significant milestone in its ongoing expansion and mission to redefine what's possible in pharmaceutical compounding with the acquisition of a state-of-the-art manufacturing facility in Alachua, FL., and the expansion of Strive's Tampa operations. These moves reflect the company's continued dedication to growth, innovation, and its core philosophy to NEVER SETTLE.
With these and other initiatives in development, Strive will operate over 700,000 square feet of combined facilities, making it the largest and most advanced compounding pharmacy network in the nation and positioned to support various needs that meet the industry's growing demand for quality compounded medications at scale.
The newly acquired 275,000-square-foot Current Good Manufacturing Practice (CGMP) facility in Alachua has high-tech production, fulfillment, and other drug manufacturing capabilities, including biologics and API. With major pharmaceutical manufacturing companies valuing the facility at upwards of $500M, Strive intends to transform it into the leading 503B outsourcing and contract manufacturing site within the next 12-18 months. Once operational, the site will significantly expand Strive's ability to deliver high-quality therapeutics through multiple channels while maintaining the company's gold-standard commitment to quality.
"This facility represents more than just growth; it's an investment in the future of patient access and pharmaceutical excellence," said Nate Hill, CEO and co-founder of Strive Pharmacy. "The Alachua site will position Strive at the forefront of innovation, allowing us to serve providers and patients on a broader scale while maintaining the precision, quality, and care that define who we are."
At the same time, Strive has completed the expansion and transfer of its Tampa location, a move designed to raise the standard for the patient experience. The new space increases production capacity and introduces a reimagined front lobby that reflects Strive's patient-first approach, warm, transparent, and service-oriented. The Tampa site strengthens Strive's presence in the Southeast, enabling faster fulfillment, improved service levels, and expanded therapeutic reach.
"Every investment we make, whether it's infrastructure, technology, or talent, is about keeping our brand promise to patients and providers," said Mike Walker, President and co-founder at Strive Pharmacy. "We're building the systems and capabilities this industry deserves, because people's health depends on it."
These initiatives underscore Strive's commitment to set the standard for quality, innovation, and patient care across the nation. The company continues to invest in breakthrough technologies, recruit top-tier talent, and strengthen its operations so that patients and providers always have access to the highest quality care and compounds.
"At Strive, we're not just expanding-we're evolving," added Walker. "We're setting a new benchmark for what it means to serve patients with excellence, transparency, and compassion."
About Strive Pharmacy:
Strive Pharmacy is on a mission to make personalized medicine mainstream. With a strong focus on quality, customization, and a commitment to putting people over profit, Strive Compounding Pharmacy is redefining what personalized healthcare can look like-one prescription at a time. Whether through brick-and-mortar partnerships or innovative telehealth collaborations, Strive Compounding Pharmacy continues to push the boundaries of what's possible in modern medicine. For more information, visit Strive Compounding Pharmacy's website at https://www.strivepharmacy.com/.
Media Contact:
Zach Shurtleff
Chief Marketing Officer
[email protected]
www.strivepharmacy.com
SOURCE: Strive Pharmacy
View the original press release on ACCESS Newswire
F.Dubois--AMWN

